Nasopharyngeal Diseases  >>  MK-2206  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-2206 / Merck (MSD)
NCT01349933: Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Checkmark AACR-NCI-EORTC 2013
Oct 2013 - Oct 2013: AACR-NCI-EORTC 2013
Completed
2
21
US, RoW
Akt inhibitor MK2206, MK2206
National Cancer Institute (NCI)
Recurrent Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx
10/13
10/13
NCT01370070: MK-2206 in Recurrent Nasopharyngeal Carcinoma

Completed
2
12
RoW
MK-2206
Chinese University of Hong Kong
Recurrent Nasopharyngeal Carcinoma
12/16
01/17

Download Options